Prevalence and severity of "benign" mutations in the β-myosin heavy chain, cardiac troponin T, and α-tropomyosin genes in hypertrophic cardiomyopathy

Sara L. Van Driest, Michael John Ackerman, Steve R. Ommen, Rameen Shakur, Melissa L. Will, Rick A. Nishimura, A. Jamil Tajik, Bernard J. Gersh

Research output: Contribution to journalArticle

149 Citations (Scopus)

Abstract

Background - Genotype-phenotype correlative studies have implicated 8 particular mutations that cause hypertrophic cardiomyopathy (HCM) as "benign defects," associated with near-normal survival: N232S, G256E, F513C, V606M, R719Q, and L908V of β-myosin heavy chain (MYH7); S179F of troponin T (TNNT2); and D175N of α-tropomyosin (TPM1). Routine genetic screening of HCM patients for specific mutations is anticipated to provide important diagnostic and prognostic information. The frequency and associated phenotype of these mutations in a large, unselected cohort of HCM is unknown. Methods and Results - A total of 293 unrelated HCM patients were genotyped for the presence of a benign mutation. DNA was obtained after informed consent; specific MHY7, TNNT2, and TPM1 fragments were amplified by polymerase chain reaction; and the mutations were detected by denaturing high-performance liquid chromatography and automated DNA sequencing. Only 5 (1.7%) of the 293 patients possessed a benign mutation. Moreover, all 5 subjects with an ascribed benign mutation had already manifested clinically severe expression of HCM, with all 5 requiring surgical myectomy, 3 of the 5 having a family history of sudden cardiac death, and 1 adolescent requiring an orthotopic heart transplant. Conclusions - These findings demonstrate the rarity of specific mutations in HCM and challenge the notion of mutation-specific clinical outcomes. Fewer than 2% of the subjects harbored a benign mutation, and those patients with a benign mutation experienced a very serious clinical course.

Original languageEnglish (US)
Pages (from-to)3085-3090
Number of pages6
JournalCirculation
Volume106
Issue number24
DOIs
StatePublished - Dec 10 2002

Fingerprint

Tropomyosin
Troponin T
Myosin Heavy Chains
Hypertrophic Cardiomyopathy
Mutation
Genes
Phenotype
Sudden Cardiac Death
Genetic Testing
Informed Consent
DNA Sequence Analysis
Genotype
High Pressure Liquid Chromatography

Keywords

  • Cardiomyopathy
  • Death, sudden
  • Genetics
  • Hypertrophy

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Prevalence and severity of "benign" mutations in the β-myosin heavy chain, cardiac troponin T, and α-tropomyosin genes in hypertrophic cardiomyopathy. / Van Driest, Sara L.; Ackerman, Michael John; Ommen, Steve R.; Shakur, Rameen; Will, Melissa L.; Nishimura, Rick A.; Tajik, A. Jamil; Gersh, Bernard J.

In: Circulation, Vol. 106, No. 24, 10.12.2002, p. 3085-3090.

Research output: Contribution to journalArticle

Van Driest, Sara L. ; Ackerman, Michael John ; Ommen, Steve R. ; Shakur, Rameen ; Will, Melissa L. ; Nishimura, Rick A. ; Tajik, A. Jamil ; Gersh, Bernard J. / Prevalence and severity of "benign" mutations in the β-myosin heavy chain, cardiac troponin T, and α-tropomyosin genes in hypertrophic cardiomyopathy. In: Circulation. 2002 ; Vol. 106, No. 24. pp. 3085-3090.
@article{27bfef66da364e28a1730685b5d64658,
title = "Prevalence and severity of {"}benign{"} mutations in the β-myosin heavy chain, cardiac troponin T, and α-tropomyosin genes in hypertrophic cardiomyopathy",
abstract = "Background - Genotype-phenotype correlative studies have implicated 8 particular mutations that cause hypertrophic cardiomyopathy (HCM) as {"}benign defects,{"} associated with near-normal survival: N232S, G256E, F513C, V606M, R719Q, and L908V of β-myosin heavy chain (MYH7); S179F of troponin T (TNNT2); and D175N of α-tropomyosin (TPM1). Routine genetic screening of HCM patients for specific mutations is anticipated to provide important diagnostic and prognostic information. The frequency and associated phenotype of these mutations in a large, unselected cohort of HCM is unknown. Methods and Results - A total of 293 unrelated HCM patients were genotyped for the presence of a benign mutation. DNA was obtained after informed consent; specific MHY7, TNNT2, and TPM1 fragments were amplified by polymerase chain reaction; and the mutations were detected by denaturing high-performance liquid chromatography and automated DNA sequencing. Only 5 (1.7{\%}) of the 293 patients possessed a benign mutation. Moreover, all 5 subjects with an ascribed benign mutation had already manifested clinically severe expression of HCM, with all 5 requiring surgical myectomy, 3 of the 5 having a family history of sudden cardiac death, and 1 adolescent requiring an orthotopic heart transplant. Conclusions - These findings demonstrate the rarity of specific mutations in HCM and challenge the notion of mutation-specific clinical outcomes. Fewer than 2{\%} of the subjects harbored a benign mutation, and those patients with a benign mutation experienced a very serious clinical course.",
keywords = "Cardiomyopathy, Death, sudden, Genetics, Hypertrophy",
author = "{Van Driest}, {Sara L.} and Ackerman, {Michael John} and Ommen, {Steve R.} and Rameen Shakur and Will, {Melissa L.} and Nishimura, {Rick A.} and Tajik, {A. Jamil} and Gersh, {Bernard J.}",
year = "2002",
month = "12",
day = "10",
doi = "10.1161/01.CIR.0000042675.59901.14",
language = "English (US)",
volume = "106",
pages = "3085--3090",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "24",

}

TY - JOUR

T1 - Prevalence and severity of "benign" mutations in the β-myosin heavy chain, cardiac troponin T, and α-tropomyosin genes in hypertrophic cardiomyopathy

AU - Van Driest, Sara L.

AU - Ackerman, Michael John

AU - Ommen, Steve R.

AU - Shakur, Rameen

AU - Will, Melissa L.

AU - Nishimura, Rick A.

AU - Tajik, A. Jamil

AU - Gersh, Bernard J.

PY - 2002/12/10

Y1 - 2002/12/10

N2 - Background - Genotype-phenotype correlative studies have implicated 8 particular mutations that cause hypertrophic cardiomyopathy (HCM) as "benign defects," associated with near-normal survival: N232S, G256E, F513C, V606M, R719Q, and L908V of β-myosin heavy chain (MYH7); S179F of troponin T (TNNT2); and D175N of α-tropomyosin (TPM1). Routine genetic screening of HCM patients for specific mutations is anticipated to provide important diagnostic and prognostic information. The frequency and associated phenotype of these mutations in a large, unselected cohort of HCM is unknown. Methods and Results - A total of 293 unrelated HCM patients were genotyped for the presence of a benign mutation. DNA was obtained after informed consent; specific MHY7, TNNT2, and TPM1 fragments were amplified by polymerase chain reaction; and the mutations were detected by denaturing high-performance liquid chromatography and automated DNA sequencing. Only 5 (1.7%) of the 293 patients possessed a benign mutation. Moreover, all 5 subjects with an ascribed benign mutation had already manifested clinically severe expression of HCM, with all 5 requiring surgical myectomy, 3 of the 5 having a family history of sudden cardiac death, and 1 adolescent requiring an orthotopic heart transplant. Conclusions - These findings demonstrate the rarity of specific mutations in HCM and challenge the notion of mutation-specific clinical outcomes. Fewer than 2% of the subjects harbored a benign mutation, and those patients with a benign mutation experienced a very serious clinical course.

AB - Background - Genotype-phenotype correlative studies have implicated 8 particular mutations that cause hypertrophic cardiomyopathy (HCM) as "benign defects," associated with near-normal survival: N232S, G256E, F513C, V606M, R719Q, and L908V of β-myosin heavy chain (MYH7); S179F of troponin T (TNNT2); and D175N of α-tropomyosin (TPM1). Routine genetic screening of HCM patients for specific mutations is anticipated to provide important diagnostic and prognostic information. The frequency and associated phenotype of these mutations in a large, unselected cohort of HCM is unknown. Methods and Results - A total of 293 unrelated HCM patients were genotyped for the presence of a benign mutation. DNA was obtained after informed consent; specific MHY7, TNNT2, and TPM1 fragments were amplified by polymerase chain reaction; and the mutations were detected by denaturing high-performance liquid chromatography and automated DNA sequencing. Only 5 (1.7%) of the 293 patients possessed a benign mutation. Moreover, all 5 subjects with an ascribed benign mutation had already manifested clinically severe expression of HCM, with all 5 requiring surgical myectomy, 3 of the 5 having a family history of sudden cardiac death, and 1 adolescent requiring an orthotopic heart transplant. Conclusions - These findings demonstrate the rarity of specific mutations in HCM and challenge the notion of mutation-specific clinical outcomes. Fewer than 2% of the subjects harbored a benign mutation, and those patients with a benign mutation experienced a very serious clinical course.

KW - Cardiomyopathy

KW - Death, sudden

KW - Genetics

KW - Hypertrophy

UR - http://www.scopus.com/inward/record.url?scp=0037058868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037058868&partnerID=8YFLogxK

U2 - 10.1161/01.CIR.0000042675.59901.14

DO - 10.1161/01.CIR.0000042675.59901.14

M3 - Article

VL - 106

SP - 3085

EP - 3090

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 24

ER -